With 2.14 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.23 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $68.73 whereas the lowest price it dropped to was $65.22. The 52-week range on INSM shows that it touched its highest point at $84.91 and its lowest point at $21.92 during that stretch. It currently has a 1-year price target of $97.00. Beta for the stock currently stands at 0.79.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of INSM was up-trending over the past week, with a rise of 0.62%, but this was down by -7.33% over a month. Three-month performance dropped to -21.04% while six-month performance fell -0.41%. The stock gained 166.53% in the past year, while it has lost -4.37% so far this year. A look at the trailing 12-month EPS for INSM yields -5.95 with Next year EPS estimates of -3.66. For the next quarter, that number is -1.30. This implies an EPS growth rate of 6.01% for this year and 30.09% for next year. EPS is expected to grow by 47.10% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -13.12%.
Float and Shares Shorts:
At present, 181.90 million INSM shares are outstanding with a float of 178.11 million shares on hand for trading. On 2025-04-30, short shares totaled 15.78 million, which was 867.0 higher than short shares on 1743379200. In addition to Mr. William H. Lewis J.D., M.B.A. as the firm’s President, CEO & Chairman, Ms. Sara M. Bonstein M.B.A. serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 1.1569 of INSM’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, INSM reported revenue of $92823000.0 and operating income of -$229840000.0. The EBITDA in the recently reported quarter was -$228384000.0 and diluted EPS was -$1.42.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for INSM since 14 analysts follow the stock currently. There are 13 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With INSM analysts setting a high price target of 109.0 and a low target of 80.0, the average target price over the next 12 months is 96.78389. Based on these targets, INSM could surge 65.1% to reach the target high and rise by 21.18% to reach the target low. Reaching the average price target will result in a growth of 46.6% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$5.22551 being high and -$5.58112 being low. For INSM, this leads to a yearly average estimate of -$5.3638.
